Glasdegib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Glasdegib. Educational only — not medical advice.
Labeled uses
DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Source: FDA labeling via NIH DailyMed (set 204a6f7e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.